Abstract:Objective: To investigate the clinical significance of suppressor of cytokine signaling 1 (SOCS1) hypermethylation in typical myelo-proliferative neoplasms (MPNs), and to discuss the potential mechanism. Methods: Methylation specific PCR was used to detect the hypermethylation status of SOCS1 gene in bone marrow specimens from patients with typical MPNs. Granulocyte colony stimulating factor (G-CSF) was used as a chemical inducer to simulate the MPNs cells for different time, then the real-time quantitative PCR and Western blotting were applied to evaluate the expressions of SOCS1 mRNA and protein, respectively. After the demethylating agent 2-deoxyazacytidin was used to cultivate MPNs cells for different time, SOCS1 mRNA expression was detected by real-time quantitative PCR. Results: Hypermethylation of SOCS1 was detected in 27 of 100 (27.0%) cases of MPNs. The expressions of SOCS1 mRNA in the MPNs cells were significantly decreased after G-CSF intervention in the SOCS1 hypermethylation groups as compared with those in the non-methylation groups (P0.05). The expressions of SOCS1 protein in the SOCS1 hypermethylation groups from patients with MPNs were decreased, but there was no statistically significant difference as compared with normal controls (P0.05). In addition, SOCS1 mRNA expression was markedly promoted in MPNs cells after treatment with the demethylating agent as compared with the hypermethylated groups induced by G-CSF The roles of hypermethylation and demethylation of suppressor of cytokine signaling 1 gene in typical myelo-proliferative neoplasms QIN Wei, LU Hui-na, HUANG Bin-bin, XIU Bing, BO Lan-jun, GAO Qing-mei, ZHANG Wen-jun, LIANG Ai-bin Department of Hematology, Tongji Hospital, Tongji University, Shanghai 200065, China Abstract Objective: To investigate the clinical significance of suppressor of cytokine signaling 1 (SOCS1) hypermethylation in typical myelo-proliferative neoplasms (MPNs), and to discuss the potential mechanism. Methods: Methylation specific PCR was used to detect the hypermethylation status of SOCS1 gene in bone marrow specimens from patients with typical MPNs. Granulocyte colony stimulating factor (G-CSF) was used as a chemical inducer to simulate the MPNs cells for different time, then the real-time quantitative PCR and Western blotting were applied to evaluate the expressions of SOCS1 mRNA and protein, respectively. After the demethylating agent 2-deoxyazacytidin was used to cultivate MPNs cells for different time, SOCS1 mRNA expression was detected by real-time quantitative PCR. Results: Hypermethylation of SOCS1 was detected in 27 of 100 (27.0%) cases of MPNs. The expressions of SOCS1 mRNA in the MPNs cells were significantly decreased after G-CSF intervention in the SOCS1 hypermethylation groups as compared with those in the non-methylation groups (P0.05). The expressions of SOCS1 protein in the SOCS1 hypermethylation groups from patients with MPNs were decreased, but there was no statistically significant difference as compared with normal controls (P0.05). In addition, SOCS1 mRNA expression was markedly promoted in MPNs cells after treatment with the demethylating agent as compared with the hypermethylated groups induced by G-CSF (P0.05). Conclusion: Hypermethylation of SOCS1 exists in MPNs, and the hypermethylation of CpG can inhibit the expression of SOCS1 gene. After demethylation, the expression of SOCS1 gene increases in MPNs. These suggest that the SOCS1 hypermethylation may be associated with the risk of MPNs. Demethylation may become a potential therapeutic strategy for MPNs.

Deletion of the P15 Gene and Promoter Methylation in the Bone Marrow of Patients with Myelodysplastic Syndromes

Study on Methylation of P15ink4b Gene and Its Mechanisms in Patients with Myelodysplastic Syndrome and Leukemia.

Methylation Analysis of the Wnt Antagonist in Myelodysplastic Syndrome

[Methylation of P15INK4B Gene in Patients with Myelodysplastic Syndromes and Demethylating Effects of Drugs].

Methylation status of p15~(INK4B) gene in patients with myelodysplastic syndromes

Research status of p53 in the pathogenesis of 5q-syndrome

[Detection of Methylation Levels of Multi-Genes by Real-Time PCR in Patients with Myelodysplastic Syndrome].

To Investigate the Relationship Between P15INK4B Gene Promoter Methylation Degree and Different Types of MDS and Prognosis

[Study of Aberrant P73 Promoter Methylation in Patients with Myelodysplastic Syndrome].

[Experimental Study of SHP-1 Promoter Methylation in Myelodysplastic Syndromes and Its Related Mechanism].

Methylation of the P73 Gene in Patients with Myelodysplastic Syndromes: Correlations with Apoptosis and Prognosis.

Aberration Ofp73promoter Methylation Inde Novomyelodysplastic Syndrome

Methylation of Wnt antagonist genes: a useful prognostic marker for myelodysplastic syndrome

[Abnormality of P15(ink4b) Gene and Myelodysplastic Syndrome].

Clinical significance of BCL2L10 expression and promoter methylation in myelodysplastic syndrome

Aberrant Methylation Of Death-Associated Protein Kinase 1 Cpg Islands In Myelodysplastic Syndromes

The clinicopathological significance of HES1 promoter hypomethylation in patients with colorectal cancer.

Hypermethylation of SHP-1 Promoter in Patient with High-Risk Myelodysplastic Syndrome and It Predicts Poor Prognosis

Hypomethylation of MIR-378 5'-flanking region predicts poor survival in young patients with myelodysplastic syndrome

Effect of P15~(ink4b) Gene Methylation in Myelodysplastic Syndromes' Progressing:A Meta-analysis of Literature

The roles of hypermethylation and demethylation of suppressor of cytokine signaling 1 gene in typical myelo-proliferative neoplasms